Robin L Jones

73PUBLICATIONS
279CO-AUTHORS
Molecular targetsComparative language studiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Globalisation and cultureEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (73)

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|May 04, 2026
Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

|Mar 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Mrinal Gounder, Patrick Schöffski, Robin L Jones

|Jan 29, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

Robin L Jones, Roman Groisberg, Jean-Yves Blay

|Jun 11, 2025
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions.

Stefania Kokkali, Ana Dolcan, Kjetil Boye

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

Pageof 13

Frequent Collaborators

19 joint publications

Paul Huang

12 joint publications

Jean-Yves Blay

8 joint publications

Sebastian Bauer

8 joint publications

Michael C Heinrich